Virus filtration is a technique used for removal of viruses from biological products and sample preparation. It finds wide applications in production of vaccines and gene therapy vectors. Virus filters helps in production of safer and consistent biological drugs such as monoclonal antibodies, sterile injectable drugs and vaccines. With rising prevalence of infectious viruses, demand for virus removal filters are increasing significantly.
The global Virus Filtration Market is estimated to be valued at Us$ 5.86 Mn in 2024 and is expected to exhibit a CAGR Of 3.1% over the forecast period 2024 To 2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
Increasing R&D investments by biopharmaceutical companies to develop novel biologics such as monoclonal antibodies, gene therapy vectors and vaccines is expected to drive the demand for virus filtration membrane filters. Moreover, growing concerns regarding safety of biologics and biosimilars has impelled regulatory bodies to incorporate virus filtration step in the manufacturing process of biotherapeutics. Large investments in development of vaccines for infectious diseases will augment the adoption of virus filtration techniques. Advancements in virus filtration systems with improved throughput and removal efficiencies will further provide new opportunities in coming years.
Porter's Analysis
Threat of new entrants: Low capital requirements and established distribution channels lower the threat of new entrants. However, strict regulatory approvals and need for large downstream purification lowers threat.
Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power as buyers due to their scale and can negotiate on price. However, need for impurity-free products increase dependence.
Bargaining power of suppliers: Few players operating at a global scale results in high bargaining power of membrane suppliers and other consumables. Proprietary technologies also provide advantage.
Threat of new substitutes: No close substitutes exist for virus filtration as it is critical for large molecule purity. However, continuous improvement in other purification techniques poses medium threat.
Competitive rivalry: Presence of large multinational players results in high competition. Focus on single-use technologies, continuous processing and capacity expansion intensifies rivalry.
SWOT Analysis
Strengths: Strict regulations ensure growth in biopharma. Technologies like Planova filters enhance recovery rates.
Weaknesses: High capital cost of virus retentive membranes. Optimization challenges for continuous modalities.
Opportunities: Emerging markets growth and single-use systems drive opportunity. Cell and gene therapy demands new solutions.
Threats: Price control policies in some countries. Membrane fouling issues raise complexity.
Key Takeaways
The Global Virus Filtration Market Demand is expected to witness high growth driven by biologics demand and patent expiries. The market size is projected to reach US$ 8.45 billion by 2031 from US$ 5.86 billion in 2024, registering a CAGR of 3.1% during the forecast period.
North America dominates currently due to presence of majority biopharma players. Higher adoption of single-use technologies and continuous processing also contribute to regional leadership. Asia Pacific is poised to emerge as the fastest growing market led by China, India and South Korea. Increasing biosimilars production and rising R&D investments would accelerate regional growth rate.
Key players operating in the virus filtration market are Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Merck KGaA, Danaher Corporation and Sartorius AG. These established players focus on capacity expansions, membrane technologies and services to capitalize on the growth opportunities.
Get more insights on this topic :
